Skip to main
RAPP
RAPP logo

RAPP Market Capitalization Overview

Market Cap: $412.79M as of Jul 1, 2025

$412.79M
Past Month+$110.96M (36.76%)
As of Jul 1, 2025, RAPP has a market capitalization of $412.79M. Over the past 30 days, its market cap has increased by 20.32%, while in the last 12 months, it has decreased by -36.38%.

Market capitalization represents the total value of Rapport Therapeutics Inc as perceived by the stock market. It is calculated by multiplying the current stock price by the total number of outstanding shares.

RAPP Market Cap Formula = Stock Price * Shares Outstanding

The market cap of RAPP helps investors assess the company's size and compare it with competitors for better investment decisions.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

RAPP Market Cap History

DateMarket CapChange
Jul 1, 2025$412.79M+20.32%
Jun 2, 2025$343.08M-18.05%
May 1, 2025$418.63M+19.98%
Apr 1, 2025$348.91M+33.41%
Mar 3, 2025$261.53M-56.93%
Feb 3, 2025$607.17M-9.73%
Jan 2, 2025$672.65M-23.38%

RAPP End of Year Market Cap History

DateMarket CapChange
2025$412.79M-36.38%
2024$648.87M

FAQs About Rapport Therapeutics Inc (RAPP) Market Cap

As of Jul 1, 2025, the market capitalization of RAPP is $412.79M. Market cap represents the total value of a company’s outstanding shares and is a key indicator of its size in the stock market.

In the last 30 days, Rapport Therapeutics Inc’s market capitalization has increased by 36.76%, changing from $301.84M to $412.79M as of Jul 1, 2025.

In the last 3 months, Rapport Therapeutics Inc’s market capitalization has increased by —, changing from – to – as of –.

In the year 2024, Rapport Therapeutics Inc’s market capitalization increased from – in January to $648.87M in December, reflecting a — change.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.